What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2023-10-30 compared with 2022-10-31 · 85 added, 9 removed, 30 unchanged (76% of the section changed)

3 unchanged sentences

symbol “ODYY.” The following table sets forth the bid prices quoted for our common stock during each quarter, as reported

by the OTCPink in the last two fiscal years.

The following quotations reflect inter-dealer prices, without retail mark-up, markdown or

commission and may not necessarily represent actual transactions.

by the OTCQB in the last two fiscal years.

The following quotations reflect inter-dealer prices, without retail mark-up, markdown or commission

and may not necessarily represent actual transactions.

Fiscal Year Ended July 31, 2023

12 unchanged sentences

Holders of our Common Stock

As of October 31, 2022, 71,994,154 shares of

our common stock were outstanding.

As of October 30, 2023, 81,495,269 shares of our

common stock were outstanding.

There are approximately 2,500 stockholders of record.

8 unchanged sentences

Discussion and Analysis of Financial Condition and Results of Operations.”

Securities Authorized for Issuance Under

Equity Compensation Plans

See Item 12 of this report

for disclosure regarding securities authorized for issuance under equity compensation plans required by Item 201(d) of Regulation S-K.

Securities Authorized for Issuance Under Equity

Compensation Plans

See Item 12 of this report for disclosure regarding

securities authorized for issuance under equity compensation plans required by Item 201(d) of Regulation S-K.

Recent Sales of Unregistered Securities

Unreported sales of unregistered securities were

In fiscal 2023 and 2022,

the Board granted the following stock options and restricted stock units (“RSUs”):

Stock Options

stock options

exercise price

stock options

exercise price

Military advisory board

Scientific advisory board

Sports advisory board

Restricted Stock Units

exercise price

Stock options and RSUs granted to directors, officers

and employees were in exchange for ongoing services in their respective capacities.

The stock options and RSUs granted to others were

in exchange for services provided in an amount equal to the fair value of awards granted.

In June 2021, we sold 500,000 shares of our common

stock at $0.59 per share along with a five-year share purchase warrant exercisable for 500,000 shares of our common stock at a price of

$1.00 per share, for a total aggregate purchase price of $295,000 to Tysadco, an accredited investor, which also provided certain consulting

services to us.

The purchase price was paid with $250,000 cash and the satisfaction of $45,000 of amounts due to Tysadco for its consulting

In August 2021, in connection with Tysadco convertible

debt financing, we issued Tysadco 200,000 shares of our common stock with a value of $17,718.

In October 2021, in connection with an equity

financing with LPC, to which we received $250,000 in cash from LPC and LPC received (i) 1,500,000 restricted shares of our common stock,

and (ii) 833,333 warrants exercisable at $0.50 per common share expiring in five years.

In October 2021, in connection with an equity

financing with Tysadco, to which we received $250,000 in cash from Tysadco and Tysadco received (i) 1,500,000 restricted shares of our

common stock, and (ii) 833,333 warrants exercisable at $0.50 per common share expiring in five years.

In February 2022, in connection with an amendment

to the LGH Note, we issued LGH 100,000 shares of our common stock with a value of $51,000.

In February 2022, in

connection with an investor relations consulting agreement with Tysadco, we issued Tysadco 3,000,000 restricted shares of our common stock

valued at $0.53 per share.

The agreement includes a leak out provision until the shares have been sold.

In May and July 2022, we entered into consulting

agreements for investor relations services.

We granted the investor relations firms a total of 745,000 shares of our common stock valued

at an average price of $0.23 per share for a total value of $171,650.

In June 2022, in connection

with our agreement with Prevacus entered into on March 1, 2021, we issued Prevacus 1,000,000 shares of our common stock with a value of

$77,800 related to the successful first dosing in our Phase I clinical trial related to our ONP-002 neurosteroid concussion treatment.

In September and October 2022 and March 2023,

in connection with entering into consulting agreements, we issued consultants 2,300,000 shares of our common stock valued at an average

price of $0.19 per share for a total value of $433,800.

In September 2022, we

entered into a promissory note for $30,000 with a consultant for investor relations services with an interest rate of 8% per annum and

a due date of December 31, 2022.

On December 30, 2022, this promissory note was amended to extend the maturity date to January 31, 2023.

On January 31, 2023, the note was extended to June 30, 2023.

As consideration, the consultant was granted a five-year stock option for

50,000 shares of common stock at $0.17 per share with a value of $7,700.

On June 9, 2023, we entered into Amendment No.

2 to this promissory

note pursuant to which we converted the loan into 300,000 shares of our common stock with a value of $36,000.

In November 2022, in connection with the Option

Agreement with Prevacus, we issued 1,000,000 shares of our common stock with a value of $0.17 per share for a total value of $170,000.

In December 2022, we entered into a Securities

Purchase Agreement (the “SPA”) with Mast Hill Fund, L.P.

(“Mast Hill”).

We issued a five-year share purchase warrant

entitling Mast Hill to acquire 2,000,000 shares of our common stock at $0.20 per share with a value of $274,000 and a five-year warrant

for 4,000,000 shares of our common stock at $0.20 per share with a value of $548,000 issuable in the event of default.

In connection with

the agreement, we issued Carter Terry & Company, Inc.

213,725 shares of our common stock valued at $13,443.

In June 2023, we entered into Amendment No.

to the SPA dated December 13, 2022.

Pursuant to the Amendment, we issued a five-year common stock purchase warrant to Mast Hill Fund L.P.

for the purchase of 1,000,000 shares of our common stock at $0.20 per share with a fair value of $28,448.

In June 2023, Mast Hill converted $40,250 of accrued

interest and $1,750 of fees for a total of $42,000 into 560,000 shares of our common stock.

In issuing these shares, we relied on an exemption

from the registration requirements of the Securities Act of 1933 provided by Section 4(a)(2) of the Securities Act of 1933.

Issuer Purchases of Equity Securities

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity